Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

NEXT STORY
Study of Cancer Patients and COVID-19 Highlights Health Disparities
PREV STORY
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi et Regeneron annoncent les résultats positifs d’une étude de phase 2 du dupilumab dans le traitement de l’oesophagite à éosinophiles modérée à sévère de l’adulte

Sanofi et Regeneron annoncent les résultats positifs d'une étude de phase 2 du dupilumab ...

author_avatar
NASDAQ Market News

Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million

author_avatar
NASDAQ Market News

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

author_avatar
NASDAQ Market News